CriticalProkinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)×Macrolide antibiotic
Updated · Methodology
Mechanism
Erythromycin is a moderate inhibitor of CYP3A4 and of the transporter P-glycoprotein, so drugs that the cytochrome P450 system metabolises may reach higher blood levels (erythromycin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Raised cisapride levels have been found in people taking erythromycin and cisapride together, and high cisapride levels can prolong the QT interval and cause ventricular arrhythmias (erythromycin SmPC, AEMPS). According to the US erythromycin label, the most likely cause is that erythromycin inhibits the breakdown of cisapride in the liver (erythromycin label, US Food and Drug Administration, FDA). Erythromycin itself also prolongs the QT interval. In people treated with macrolides, erythromycin included, QT prolongation with a risk of arrhythmia and torsade de pointes has been seen, and deaths have been reported (erythromycin SmPC, AEMPS).
Symptoms
High cisapride levels with erythromycin can cause QT prolongation, ventricular tachycardia, ventricular fibrillation and torsade de pointes (erythromycin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Post-marketing reports include deaths with this combination (erythromycin label, US Food and Drug Administration, FDA). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while a ventricular arrhythmia causes sudden strong palpitations, dizziness or fainting and can lead to cardiac arrest. Older people may be more susceptible to drug effects on the QT interval (erythromycin FDA label).
Management
The combination is contraindicated. The Spanish erythromycin summaries of product characteristics (SmPCs), for oral and intravenous use, contraindicate erythromycin in people taking cisapride (erythromycin SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The US erythromycin label also contraindicates it with cisapride (erythromycin label, US Food and Drug Administration, FDA). Cisapride is not in the Spanish medicines register CIMA, so the level of risk comes from the erythromycin documents. If a person takes cisapride obtained in another country, do not prescribe erythromycin (erythromycin SmPCs, AEMPS, and FDA label). Erythromycin is also contraindicated with a history of QT prolongation or ventricular arrhythmia, including torsade de pointes, and with low potassium or magnesium (erythromycin SmPCs, AEMPS). Use it with caution in coronary artery disease, severe heart failure, conduction disorders and clinically significant bradycardia (erythromycin SmPCs, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Eritromicina (nº registro 79380), sección 4.3 (2025)– AEMPS, CIMA, nº registro 79380, sección 4.3
- FDA: E.E.S. (erythromycin ethylsuccinate) prescribing information (2025)– FDA, DailyMed, Carnegie Pharmaceuticals LLC, setid 91479d92-3bf3-4eb3-81bd-8ce4956d4347, revised 02/2025, Contraindications, Warnings – QT Prolongation, Precautions – Drug Interactions
- AEMPS: Ficha técnica: Eritromicina (nº registro 55771), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55771 (Pantomicina 1 g polvo para solución para perfusión), revisión 09/2025, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Eritromicina (nº registro 55771), sección 4.5 (2025)– AEMPS, CIMA, nº registro 55771 (Pantomicina 1 g polvo para solución para perfusión, Amdipharm), revisión 09/2025 (texto revisado 02/2023), secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Eritromicina (nº registro 58767), sección 4.3 (2025)– AEMPS, CIMA, nº registro 58767 (Pantomicina 100 mg/ml granulado para suspensión oral, Amdipharm), revisión 11/2025 (texto revisado 05/2024), secciones 4.3, 4.4 y 4.5